Authors
Kathryn Richardson, Chris Fox, Ian Maidment, Nicholas Steel, Yoon K Loke, Antony Arthur, Phyo K Myint, Carlota M Grossi, Katharina Mattishent, Kathleen Bennett, Noll L Campbell, Malaz Boustani, Louise Robinson, Carol Brayne, Fiona E Matthews, George M Savva
Publication date
2018/4/25
Journal
bmj
Volume
361
Publisher
British Medical Journal Publishing Group
Description
Objectives
To estimate the association between the duration and level of exposure to different classes of anticholinergic drugs and subsequent incident dementia.
Design
Case-control study.
Setting
General practices in the UK contributing to the Clinical Practice Research Datalink.
Participants
40 770 patients aged 65-99 with a diagnosis of dementia between April 2006 and July 2015, and 283 933 controls without dementia.
Interventions
Daily defined doses of anticholinergic drugs coded using the Anticholinergic Cognitive Burden (ACB) scale, in total and grouped by subclass, prescribed 4-20 years before a diagnosis of dementia.
Main outcome measures
Odds ratios for incident dementia, adjusted for a range of demographic and health related covariates.
Results
14 453 (35%) cases and 86 403 (30%) controls were prescribed at least one anticholinergic drug with an ACB score of 3 (definite anticholinergic …
Scholar articles
K Richardson, C Fox, I Maidment, N Steel, YK Loke… - bmj, 2018
K Richardson, C Fox, I Maidment, N Steel, YK Loke… - 2018